Savara to Present at the JMP Securities Life Sciences Conference
June 13 2019 - 4:02PM
Business Wire
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company,
today announced that the Company's Chief Executive Officer, Rob
Neville, and Chief Operating Officer, Taneli Jouhikainen, will
present at the JMP Securities Life Sciences Conference on
Wednesday, June 19, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m.
Pacific Time in the Fontainebleau room, The St. Regis, New
York.
Interested parties can access a live audio webcast on the
Investors page of the Savara website at
www.savarapharma.com/investors/events-presentations/. Please
connect to the Company's website at least 15 minutes prior to the
start of the presentation to ensure sufficient time for any
software download that may be required for the webcast. An archived
presentation will be available on Savara's website for 30 days.
About Savara
Savara is an orphan lung disease company. Savara’s pipeline
comprises Molgradex, an inhaled granulocyte-macrophage
colony-stimulating factor (GM-CSF) in Phase 3 development for
autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a
development for nontuberculous mycobacterial (NTM) lung infection
in both non-cystic fibrosis (CF) and CF-affected individuals with
chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled
vancomycin for treatment of persistent methicillin-resistant
Staphylococcus aureus (MRSA) lung infection in CF. Savara’s
strategy involves expanding its pipeline of potentially
best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of
becoming a leading company in its field. The most recent
acquisition is aerosolized amikacin/fosfomycin, a Phase 2-ready
combination antibiotic for which the initial indication will focus
on non-CF bronchiectasis patients with chronic lung infection and
frequent exacerbations. Savara’s management team has significant
experience in orphan drug development and pulmonary medicine,
identifying unmet needs, developing and acquiring new product
candidates, and effectively advancing them to approvals and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn:
www.linkedin.com/company/savara-pharmaceuticals/)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190613005663/en/
Savara Inc. IR & PRAnne Erickson
(anne.erickson@savarapharma.com)(512) 851-1366
For IR: Solebury TroutGitanjali Jain Ogawa
(Gogawa@troutgroup.com)(646) 378-2949
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Sep 2023 to Sep 2024